Extracellular NM23 protein promotes the growth and survival of primary cultured human acute myelogenous leukemia cells

Cancer Science

Volumn 100, Issue 10, 2009, Pages 1885-1894

  Okabe Kado, Junko ^a   Kasukabe, Takashi ^a   Honma, Yoshio ^b   Kobayashi, Hirofumi ^a   Maseki, Nobuo ^a   Kaneko, Yasuhiko ^a  

^a SAITAMA CANCER CENTER   (Japan)

^b SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEOSIDE DIPHOSPHATE KINASE A; RECOMBINANT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; EXTRACELLULAR FLUID; HUMANS; LEUKEMIA, MYELOID, ACUTE; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; PROGNOSIS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 70349606670     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01276.x     Document Type: Article

References (36)

1. Steeg PS, Bevilacqua G, Kopper L. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988, 80:200-4.
2. Lacombe ML, Milon L, Munier A, Mehus JG, Lambeth DO. The human nm23/nucleoside diphosphate kinases. J Bioenerg Biomembr 2000, 32:247-58.
3. Lascu I, Gonin P. The catalytic mechanism of nucleoside diphosphate kinases. J Bioenerg Biomembr 2000, 32:237-46.
4. MacDonald NJ, De La Rosa A, Steeg PS. The potential roles of nm23 in cancer metastasis and cellular differentiation. Eur J Cancer 1995, 31A:1096-100.
5. De La Rosa A, Williams RL, Steeg PS. Nm23/nucleoside diphosphate kinase: toward a structural and biochemical understanding of its biological functions. Bioessays 1995, 17:53-62.
6. Horak CE, Lee JH, Elkahloun AG. Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2. Cancer Res 2007, 67:7238-46.
7. Lacombe ML, Sastre-Garau X, Lascu I. Overexpression of nucleoside diphosphate kinase (Nm23) in solid tumors. Eur J Cancer 1991, 27:1302-7.
8. Hailat N, Keim DR, Melhem RF. High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification. J Clin Invest 1991, 88:341-5.
9. Leone A, Seeger RC, Hong CM. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastoma. Oncogene 1993, 8:855-65.
10. Yokoyama A, Okabe-Kado J, Wakimoto N. Evaluation by multivariate analysis of the differentiation inhibitory factor nm23 as a prognostic factor in acute myelogenous leukemia and application to other hematological malignancies. Blood 1998, 91:1845-51.
11. Niitsu N, Okabe-Kado J, Okamoto M. Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin's lymphoma. Blood 2001, 97:1202-10.
12. Okabe-Kado J, Hayashi M, Honma Y, Hozumi M. Characterization of differentiation inhibitory activity from nondifferentiating mouse myeloid leukemia cells. Cancer Res 1985, 45:4848-52.
13. Okabe-Kado J, Kasukabe T, Honma Y, Hozumi M. Purification of a factor inhibiting differentiation from conditioned medium of nondifferentiating mouse myeloid leukemia cells. J Biol Chem 1988, 263:10 994-9.
14. Okabe-Kado J, Kasukabe T, Honma Y, Hayashi M, Henzel WJ, Hozumi M. Identity of differentiation inhibiting factor for mouse myeloid leukemia cells with Nm23 protein involved in tumor metastasis. Biochem Biophys Res Commun 1992, 182:987-94.
15. Yokoyama A, Okabe-Kado J, Sakashita A. Differentiation inhibitory factor nm23 as a new prognostic factor in acute monocytic leukemia. Blood 1996, 88:3555-61.
16. Wakimoto N, Yokoyama A, Okabe-Kado J, Nagata N, Motoyoshi K, Honma Y. Combined analysis of differentiation inhibitory factor nm23-H1 and nm23-H2 as prognostic factors in acute myeloid leukaemia. Br J Cancer 1998, 77:2298-303.
17. Yamashiro S, Urano T, Shiku H, Furukawa K. Alteration of nm23 gene expression during the induced differentiation of human leukemia cell lines. Oncogene 1994, 9:2461-8.
18. Willems R, Van Bockstaele DR, Landon F. Decrease in nucleoside diphosphate kinase expression during hematopoietic maturation. J Biol Chem 1998, 273:13 663-8.
19. Niitsu N, Okabe-Kado J, Kasukabe T, Yamamoto-Yamaguchi Y, Umeda M, Honma Y. Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma. Blood 1999, 94:541-50.
20. Niitsu N, Okabe-Kado J, Nakayama M. Plasma levels of the differentiation inhibitory factor nm23-H1 protein and their clinical implications in acute myelogenous leukemia. Blood 2000, 96:1080-6.
21. Okabe-Kado J, Kasukabe T, Honma Y, Hanada R, Nakagawara A, Kaneko Y. Clinical significance of serum NM23-H1 protein in neuroblastoma. Cancer Sci 2005, 96:653-60.
22. Urano T, Furukawa K, Shiku H. Expression of nm23/NDP kinase proteins on the cell surface. Oncogene 1993, 8:1371-6.
23. Anzinger J, Malmquist NA, Gould J, Buxton ILO. Secretion of nucleoside diphosphate kinase (Nm23-H2) by cells from human breast, colon, pancreas and lung tumors. Proc West Pharmacol Soc 2001, 44:61-3.
24. Rumjahn SM, Javed MA, Wong N, Law WE, Buxton ILO. Purinergic regulation of angiogenesis by human breast carcinoma-secreted nucleoside diphosphate kinase. Br J Cancer 2007, 97:1372-80.
25. Okabe-Kado J. Serum nm23-H1 protein as a prognostic factor in hematological malignancies. Leuk Lymphoma 2002, 43:859-67.
26. MacDonald NJ, De La Rosa A, Benedict MA, Freije JMP, Krutsch H, Steeg PS. A serine phosphorylation of Nm23, and not its nucleoside diphosphate kinase activity, correlates with suppression of tumor metastatic potential. J Biol Chem 1993, 268:25 780-9.
27. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995, 82:241-50.
28. Okabe-Kado J, Kasukabe T. Physiological and pathological relevance of extracellular NM23/NDP kinases. J Bioenerg Biomemb 2003, 35:89-93.
29. Willems R, Slegers H, Rodrigus I. Extracellular nucleoside diphosphate kinase NM23/NDPK modulates normal hematopoietic differentiation. Exp Hematol 2002, 30:640-8.
30. Okabe-Kado J, Kasukabr T, Baba H, Urano T, Shiku H, Honma Y. Inhibitory action of nm23 proteins on induction of erythroid differentiation of human leukemia cells. Biochim Biophys Acta 1995, 1267:101-6.
31. Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000, 47:185-201.
32. Bharti AB, Donato N, Aggarwal BB. Curucumin (Diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003, 171:3863-71.
33. Karin M. Inflammation and cancer: the long reach of Ras. Nature Med 2005, 11:20-1.
34. Keller M, Rüegg A, Werner S, Beer H-D. Active caspase-1 is a regulator of unconventional protein secretion. Cell 2008, 132:818-31.
35. Apetoh L, Ghiringhelli F, Tesniere A. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-9.
36. Seong PY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004, 4:469-78.